Inicio>>Signaling Pathways>> MAPK Signaling>> ERK>>(R)-VX-11e

(R)-VX-11e

Catalog No.GC73082

(R)-VX-11e el compuesto 1 es un inhibidor de ERK2.

Products are for research use only. Not for human use. We do not sell to patients.

(R)-VX-11e Chemical Structure

Cas No.: 1680187-43-2

Tamaño Precio Disponibilidad Cantidad
25 mg
189,00 $
Disponible
50 mg
315,00 $
Disponible
100 mg
504,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description of (R)-VX-11e

(R)-VX-11e (Compound 1) is an ERK2 inhibitor.

References:
[1]. Vanderpool D, et al. Residence time and kinetic efficiency analysis of extracellular signal-regulated kinase 2 inhibitors. Anal Biochem. 2015 Mar 15;473:46-52.

Chemical Properties of (R)-VX-11e

Cas No. 1680187-43-2 SDF
Formula C24H20Cl2FN5O2 M.Wt 500.35
Solubility DMSO : < 1 mg/mL (insoluble or slightly soluble) Storage -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of (R)-VX-11e

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 1.9986 mL 9.993 mL 19.986 mL
5 mM 0.3997 mL 1.9986 mL 3.9972 mL
10 mM 0.1999 mL 0.9993 mL 1.9986 mL
  • Molarity Calculator

  • Dilution Calculator

  • Molecular Weight Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution) of (R)-VX-11e

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

Reseñas

Review for (R)-VX-11e

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (R)-VX-11e

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.